7.85
0.63 (8.73%)
| Penutupan Terdahulu | 7.22 |
| Jumlah Dagangan | 2,078,670 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.73 |
| Harga / Jualan (P/S) | 2.17 |
| Julat 52 Minggu |
| Margin Keuntungan | -191.50% |
| Margin Operasi (TTM) | -55.31% |
| EPS Cair (TTM) | 29.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -14.10% |
| Nisbah Semasa (MRQ) | 0.110 |
| Aliran Tunai Operasi (OCF TTM) | -145.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -114.08 M |
| Pulangan Atas Aset (ROA TTM) | -28.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Agenus Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -2.64 |
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.93% |
| % Dimiliki oleh Institusi | 33.95% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |